.
New Treatments for HIV,
Hepatitis, and Cancer
  

Proprietary and Unique Technology

HIV Technology
RFS Pharma will utilize proven technology to develop new drugs for the treatment of HIV infections. Our scientists have a great deal of experience with nucleoside reverse transcriptase inhibitors (NRTIs), which block the action of reverse transcriptase (RT) in viral replication. RFSP has several RT inhibitors that were invented by Dr. Schinazi and his colleagues at Emory University and the University of Georgia. The lead drug, currently in advanced Phase II clinical trials, is Amdoxovir® (AMDX, DAPD), a nucleoside that demonstrates good viral load reduction in the presence or absence of the key mutations responsible for the lack of response observed with other antiretrovirals. It should therefore offer an improvement over current methods of treatment. Amdoxovir® is currently in late stage Phase 2 clinical trials under a US Investigational New Drug Application (IND).


Hepatitis Technology

RFS Pharma will in-license technology that is non-toxic and effective at reducing viral load for hepatitis. Amdoxovir® has activity against HIV and HBV in cell culture and in humans. RFS Pharma is evaluating opportunities to in-license compounds that complement this product and that could be used in fixed dose combinations.